Forest Laboratories, Inc.  

(Public, NYSE:FRX)   Watch this stock  
Find more results for FRX
0.0000
Real-time:  
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E 0.00
Div/yield     -
EPS 0.60
Shares 272.59M
Beta     -
Inst. own 89%
Jul 21, 2014
Q1 2015 Forest Laboratories, Inc. Earnings Release (Estimated)
Jun 17, 2014
Forest Laboratories, Inc. Special Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2014
Net profit margin 4.95% 4.53%
Operating margin -2.55% 3.06%
EBITD margin - 17.65%
Return on average assets 2.06% 1.68%
Return on average equity 3.57% 2.78%
Employees 6,200 -
CDP Score - 56 E

Address

909 3rd Ave
NEW YORK, NY 10022-4731
United States - Map
+1-212-4217850 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Forest Laboratories, Inc. (Forest), develops, manufactures and sells branded forms of ethical drug products, which requires a physician's prescription. The Company�s products include Namenda, a N-methyl-D-aspartate (NMDA) antagonist for the treatment of moderate to severe dementia of the Alzheimer's type; Bystolic, a beta-blocker for the treatment of hypertension; Linzess, a guanylate cyclase type-C receptor agonist for the once-daily treatment for men and women suffering from IBS-C or CIC; Tudorza, a long-acting antimuscarinic agent for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and Viibryd, a SSRI and a 5-HT1A receptor partial agonist for the treatment of adults with depressive disorder (MDD). In February 2014, it acquired Aptalis. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.